| Website | nlvpartners.com |
| Phone | 212-213-0006, ext. 27 |
| Employees | |
| Founded | 2005 |
| Description | Health-Care Focused VC Firm |
| Life Sciences Fund, 10/07 | $450M |
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.
The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
| Company | Date | Round | Size | Participants |
| Neuronetics | 10/09 | Series D | $30M | 7 |
| XDx | 10/09 | Unattributed | $14.4M | 7 |
| Direct Flow Medical | 10/09 | Series C | $40M | 7 |
| Presidio | 7/09 | Unattributed | $27M | 1 |
| Interlace Medical | 7/09 | Series C | $20M | 3 |
| Spiracur | 6/09 | Series B | $20.3M | 3 |
| VaxInnate | 6/09 | Series D | $30M | 7 |
| Visiogen | 5/09 | Series D | $40M | 7 |
| ReShape Medical | 2/09 | Series B | $20M | 3 |
| Pearl Therapeutics | 7/08 | Series A | $18M | 4 |
| Concert Pharmaceuticals | 4/08 | Series C | $37M | 12 |
| Stromedix | 4/08 | Series B | $25M | 5 |
| Relypsa | 10/07 | Series A | $33M | 6 |
| Aviir | 10/07 | Series B | $11.3M | 3 |
| Intarcia Therapeutics | 3/07 | Unattributed | 5 | |
| Transcept Pharmaceuticals | 3/07 | Series D | $40M | 8 |
